Thero2-01S22

DRUG2 trials

Sponsors

Centre Regional Lutte Contre Le Cancer, Institut de cancérologie Strasbourg Europe

Conditions

HER2-positive Breast Cancermetastatic breast cancer

Phase 2

A randomized, double-blinded, placebo-controlled, multicenter, phase II/III efficacy and safety study of oral TherO2-01S22 as add-on therapy on top of first line anti-HER2 targeted treatment of patients with Metastatic Breast Cancer TherO2-01S22 in HER2-positive breast cancer: TherO2-MBC Study

Not yet recruitingCTIS2024-516576-15-00

Centre Regional Lutte Contre Le Cancermetastatic breast cancer

Target: 224Updated: 2025-12-02

Phase 3

Thero2-01S22 in HER2-positive Breast Cancer

Not yet recruitingNCT05698186

Institut de cancérologie Strasbourg EuropeHER2-positive Breast Cancer

Start: 2023-05-15End: 2027-05-15Target: 320Updated: 2023-01-26

Related Papers

heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer

BMC Cancer2024-05-246 citations